1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy

BMC Ophthalmology

Research Article

Qing Li¹  Rita Gangwani¹  Lawrence P. Iu¹  Ian Y. Wong¹  Alex Ng¹  Paul Zhao²  Xuan Shi³  Xiaoxin Li³ 

[1] Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China;Department of Ophthalmology, National University Hospital, Singapore, Singapore;Department of Ophthalmology, Peking University People’s Hospital, Beijing, China;

关键词: Age related macular degeneration;    Half-dose;    Half-fluence;    Photodynamic therapy;    Polypoidal choroidal vasculopathy;    Ranibizumab;    Verteporfin;   

DOI  :  10.1186/s12886-015-0061-8

 received in 2015-04-01, accepted in 2015-06-23,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTo evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated with a combination of anti-vascular endothelial growth factor and standard-dose photodynamic therapy (PDT). Choroidal ischemia and visual loss can be resulted from the standard-dose PDT. Half-dose PDT has proved to produce similar results and safety profile in treating central serous chorioretinopathy. Half-dose PDT may offer an alternative for PCV cases where the damage to choroidal vasculature maybe less. Here, we report the efficacy of treating PCV cases with combination of ranibizumab and half-dose PDT.MethodsIn this prospective, non-comparative, interventional case series, 19 treatment-naive eyes were treated with combined half-dose PDT and ranibizumab. All subjects were followed up for 12 months with measurement of best-corrected visual acuity (BCVA), central foveal thickness (CFT) by optical coherence tomography. Indocyanine green angiogram (ICG) was performed every 3-monthly, and subjects assessed in terms of polyp regression rates, changes in vision and central foveal thickness, need to repeat half-dose PDT. Subgroup analysis was performed based on ICG features.ResultsThe mean logMAR BCVA improved from 0.64 at baseline to 0.41 at 12 months. The mean CFT improved from 459.6mum at baseline to 384.2mum at 12 months. The difference between baseline BCVA and CFT and that at 12 months were statistically significant (both P = 0.03). Polyp regression rate after one half-dose PDT was 42.1 %. This was 61.5 % in the polyp-only group, while that in the branching-vascular-network (BVN) group was 0 % (P = <0.01).ConclusionHalf-dose PDT combined with intravitreal ranibizumab was able to induce high polyp regression rate in PCV cases that had one single polyp.

【 授权许可】

CC BY   
© Wong et al. 2015